Health Economics›Anal cancer›Metastatic disease subsequent lines of therapy

Metastatic disease subsequent lines of therapy

Anal cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~16.5 mo	~13.9 mo	~36	~R 10 330 390 PFS proxy · indirect	7
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~1.8 mo	~10.9 mo	~4	—	6

2 of 2 regimens shown